Skip to main content

RT @EBRheum: #ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores.…

Nov 12, 2019 11:29 am
Social Author Name
Mike Putman
Tweet Content
#ACR19 Abst#2728 Plenary: Upadacitinib RCT in AnkSpa Improved ASAS40 at wk14 (52% v 26% PLBO, NNT~4) and SPARCC MRI Scores. Good safety profile but too small a trial to assess properly Overall an encouraging result, JAKi impacting yet another disease! @RheumNow https://t.co/GtB9wHuoNp
Show on Archive Page
On
Display in Search Results
On
×